Jefferies analyst Biren Amin says that while the FDA approval of Regeneron's (REGN) Kevzara for the treatment of adult patients with moderate to severe active rheumatoid arthritis was expected, it is a positive. The label is in line with expectations and includes a risk of serious infections similar to Humira's (HUM) label, Amin tells investors in a research note. He notes that Regeneron disclosed a $39,000 wholesale acquisition cost for Kevzara, which is 30% lower than TNF competitors. The analyst has a Hold rating on Regeneron with a $418 price target.